Quotient Limited - Ordinary Shares (QTNT): Price and Financial Metrics


Quotient Limited - Ordinary Shares (QTNT): $0.25

-0.01 (-2.96%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

QTNT POWR Grades


  • QTNT scores best on the Growth dimension, with a Growth rank ahead of 70.47% of US stocks.
  • The strongest trend for QTNT is in Growth, which has been heading up over the past 179 days.
  • QTNT's current lowest rank is in the Momentum metric (where it is better than 16.1% of US stocks).

QTNT Stock Summary

  • Quotient Ltd's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 5.06% of US listed stocks.
  • QTNT's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 3.17% of US stocks.
  • Quotient Ltd's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -67.8%, greater than the shareholder yield of only 6.28% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Quotient Ltd, a group of peers worth examining would be OPGN, EMAN, CYRN, KLIC, and XBIO.
  • Visit QTNT's SEC page to see the company's official filings. To visit the company's web site, go to quotientbd.com.

QTNT Valuation Summary

  • In comparison to the median Healthcare stock, QTNT's price/earnings ratio is 107.95% lower, now standing at -2.9.
  • Over the past 90 months, QTNT's price/sales ratio has gone down 0.3.
  • Over the past 90 months, QTNT's price/earnings ratio has gone up 19.8.

Below are key valuation metrics over time for QTNT.

Stock Date P/S P/B P/E EV/EBIT
QTNT 2021-08-31 7.2 -6.0 -2.9 -5.5
QTNT 2021-08-30 7.1 -6.0 -2.9 -5.4
QTNT 2021-08-27 7.2 -6.1 -2.9 -5.5
QTNT 2021-08-26 7.0 -5.9 -2.9 -5.4
QTNT 2021-08-25 7.5 -6.3 -3.0 -5.6
QTNT 2021-08-24 7.8 -6.6 -3.2 -5.8

QTNT Growth Metrics

    Its 2 year cash and equivalents growth rate is now at -48.66%.
  • Its 3 year price growth rate is now at -14.01%.
  • The year over year cash and equivalents growth rate now stands at 322.7%.
Over the past 34 months, QTNT's revenue has gone up $9,232,000.

The table below shows QTNT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 38.366 -117.013 -140.089
2021-09-30 36.945 -105.643 -125.025
2021-06-30 43.544 -84.827 -112.895
2021-06-30 43.544 -84.827 -107.439
2021-03-31 43.379 -77.582 -108.47
2020-12-31 42.441 -72.626 -94.888

QTNT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • QTNT has a Quality Grade of C, ranking ahead of 30.99% of graded US stocks.
  • QTNT's asset turnover comes in at 0.172 -- ranking 207th of 682 Pharmaceutical Products stocks.
  • LGND, PLX, and NBIX are the stocks whose asset turnover ratios are most correlated with QTNT.

The table below shows QTNT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.172 0.542 -0.240
2021-03-31 0.185 0.537 -0.234
2020-12-31 0.180 0.538 -0.193
2020-09-30 0.176 0.539 -0.188
2020-06-30 0.157 0.442 -0.230
2020-03-31 0.155 0.455 -0.227

QTNT Price Target

For more insight on analysts targets of QTNT, see our QTNT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $10.25 Average Broker Recommendation 1.38 (Strong Buy)

QTNT Stock Price Chart Interactive Chart >

Price chart for QTNT

QTNT Price/Volume Stats

Current price $0.25 52-week high $4.04
Prev. close $0.25 52-week low $0.24
Day low $0.24 Volume 4,062,600
Day high $0.26 Avg. volume 971,843
50-day MA $0.46 Dividend yield N/A
200-day MA $1.58 Market Cap 25.19M

Quotient Limited - Ordinary Shares (QTNT) Company Bio


Quotient Limited develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company was founded in 2007 and is based in Penicuik, the United Kingdom.


QTNT Latest News Stream


Event/Time News Detail
Loading, please wait...

QTNT Latest Social Stream


Loading social stream, please wait...

View Full QTNT Social Stream

Latest QTNT News From Around the Web

Below are the latest news stories about Quotient Ltd that investors may wish to consider to help them evaluate QTNT as an investment opportunity.

Quotient Limited to Participate in the Cowen 42nd Annual Health Care Conference

JERSEY, Channel Islands, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced that the management team will participate in the Cowen 42nd Annual Health Care Conference. As part of the conference, the Company will be conducting a fireside chat on Wednesday, March 9, 2022 at 11:00am ET. About Quotient Limited Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnosti

Yahoo | February 22, 2022

Analysts Offer Insights on Healthcare Companies: Sonnet BioTherapeutics Holdings (SONN), Armata Pharmaceuticals (ARMP) and Quotient (QTNT)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sonnet BioTherapeutics Holdings (SONN – Research Report), Armata Pharmaceuticals (ARMP – Research Report) and Quotient (QTNT – Research Report) with bullish sentiments. Sonnet BioTherapeutics Holdings (SONN) BTIG analyst Kaveri Pohlman maintained a Buy rating on Sonnet BioTherapeutics Holdings on February 8 and set a price target of $2.00. The company's shares closed last Wednesday at $0.31, close to its 52-week low of $0.28. According to TipRanks.

Catie Powers on TipRanks | February 10, 2022

News Flash: 4 Analysts Think Quotient Limited (NASDAQ:QTNT) Earnings Are Under Threat

The latest analyst coverage could presage a bad day for Quotient Limited ( NASDAQ:QTNT ), with the analysts making...

Yahoo | February 10, 2022

Quotient GAAP EPS of -$0.44 misses by $0.17, revenue of $10.17M beats by $0.96M

Quotient press release (NASDAQ:QTNT): Q3 GAAP EPS of -$0.44 misses by $0.17. Revenue of $10.17M (+16.2% Y/Y) beats by $0.96M. Outlook for the Fiscal Year Ending March 31, 2022 The Company now expects that total product sales of Alba by Quotient reagents in the current fiscal year will be in...

Seeking Alpha | February 8, 2022

Quotient Limited (QTNT) CEO Manuel Mendez on Q3 2022 Results - Earnings Call Transcript

Quotient Limited (QTNT) Q3 2022 Earnings Conference Call February 8, 2022 08:00 ET Company Participants Ali Kiboro - Chief Financial Officer Manuel Mendez - Chief Executive Officer Conference Call Participants Josh Jennings - Cowen Matt Sykes - Goldman Sachs Brandon Couillard - Jefferies Presentation Operator Greetings and welcome to Quotient...

SA Transcripts on Seeking Alpha | February 8, 2022

Read More 'QTNT' Stories Here

QTNT Price Returns

1-mo N/A
3-mo -79.17%
6-mo -90.35%
1-year -93.61%
3-year -97.33%
5-year -96.60%
YTD -90.35%
2021 -50.29%
2020 -45.22%
2019 55.39%
2018 23.64%
2017 2.27%

Continue Researching QTNT

Want to see what other sources are saying about Quotient Ltd's financials and stock price? Try the links below:

Quotient Ltd (QTNT) Stock Price | Nasdaq
Quotient Ltd (QTNT) Stock Quote, History and News - Yahoo Finance
Quotient Ltd (QTNT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5686 seconds.